Identification of immunological predictors of COVID-19 clinical outcomes

识别 COVID-19 临床结果的免疫学预测因子

• 批准号: 10272303
• 负责人: Andrea Lisco
• 金额: $ 0.26万
• 依托单位: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10272303
• 关键词: 2019-nCoV; Biological; Blood Donations; Blood Screening; COVID-19; Clinical; Clinical Data; Collaborations; Disease; Gene Expression Profiling; Genetic; Goals; Immunologics; Individual; Infection; Integration Host Factors; Medical center; National Institute of Allergy and Infectious Disease; Outcome; Peripheral Blood Mononuclear Cell; Research Personnel; Serological; Severities; Specimen; biomarker identification; clinical predictors; comorbidity; genetic variant; human pathogen; human virome; novel; response

The extraordinarily wide spectrum of clinical manifestations associated with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection, ranging from asymptomatic to fatal disease, represent an unexpected and unexplained clinical feature for an emerging highly contagious novel human pathogen. Host factors implicated in the innate or adaptive response to SARS-Cov2 as well as comorbidities or yet unidentified predictor are likely to be associated with such broad spectrum of clinical outcomes. In collaboration with a network of southern italian medical centers (Bari, Foggia, Caserta) we have collected de-identified clinical data and biological specimens from over 300 individuals with asymptomatic infection (as identified by SARS-COv2 serological screening for blood donation), mild, moderate, severe or critical COVID-19 diseases to analyze the genetic and immunological correlates of these clinical outcomes in a collaborative project with other NIAID intramural investigators.

与严重急性呼吸综合征冠状病毒-2 (SARS-CoV-2) 感染相关的极其广泛的临床表现，从无症状到致命疾病，代表了一种新兴的高度传染性新型人类病原体的意外且无法解释的临床特征。与对 SARS-Cov2 的先天或适应性反应有关的宿主因素以及合并症或尚未确定的预测因素可能与如此广泛的临床结果有关。 我们与意大利南部医疗中心网络（巴里、福贾、卡塞塔）合作，从 300 多名无症状感染者（通过献血的 SARS-COv2 血清学筛查确定）、轻度感染者那里收集了去识别化的临床数据和生物标本。 、中度、重度或危重的 COVID-19 疾病，在与其他 NIAID 校内研究人员的合作项目中分析这些临床结果的遗传和免疫相关性。